Released On
June 21, 2022

Expires On
June 21, 2023

Media Type

Completion Time
60 minutes

Ophthalmology, Optometry

Age-related macular degeneration, AMD, Ophthalmology, Optometry

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC,in collaboration with the American Macular Degeneration Foundation (AMDF).


This activity is supported by an educational grant from Apellis Pharmaceuticals.

Credit Available

  • Physicians — 1.0 AMA PRA Category 1 Credit(s)

Target Audience

The target audiences for the HCP activity are ophthalmologists, advanced specialty practitioners, and ophthalmology nurses. Secondary audiences will include optometrists, as they play a key role in educating patients on risk factors and referring them to ophthalmologists.

Statement of Need/Program Overview

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries, and geographic atrophy (GA) secondary to AMD is responsible for approximately 20% of all cases of legal blindness. Still, many underestimate the burden of GA, a progressive and irreversible condition with few effective treatments, on patients and caregivers.

To help eye-care clinicians prepare for a paradigm shift in the management of GA, join a distinguished panel of ophthalmology experts to review the challenges in evaluating AMD and GA progression, as well as opportunities to improve monitoring with new and emerging technologies. The panel will discuss the pathophysiology underlying AMD and GA and how addressing the complement pathways could provide a viable management strategy. Current data on emerging agents for GA secondary to AMD will also be reviewed.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the negative consequences that GA secondary to AMD has on patients and caregivers and be more proactive in helping patients and caregivers maintain quality of life
  • Appraise new and emerging technologies to monitor progression of AMD and GA secondary to AMD
  • Summarize the role of complement activation in the progression of AMD and GA secondary to AMD
  • Assess the efficacy and safety of emerging treatment options targeting the complement pathway for GA secondary to AMD


Rishi P. Singh, MD

Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology, Case Western Reserve University
President, Cleveland Clinic Martin Hospital

David S. Boyer, MD

Sr. Partner
Retina-Vitreous Associates Medical Group

Joint Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology, Case Western Reserve University
President, Cleveland Clinic Martin Hospital
Consulting Fee: Apellis, Genentech, Roche,
Novartis, Graybug, Gyroscope, Asclepix
David S. Boyer, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology, Case Western Reserve University
President, Cleveland Clinic Martin Hospital
Consulting Fee:4DMT, Achillion Pharma,
Acucela, Adverum Biotech, Aerie, AiViva BIo,
Alcon, Aldeyra Therap, ALimera Sciences,
Alkahest Allegro, Allergan, Allgenesis, Alzheon,
Amgen, AMydis, Annexon BIoscience, Apellis
Pharma, Applied Genetic Tech Corp,
AsclepiX Therap, Aviceda, B&L, Bayer, Biogen,
Bionic Vision Tech, Biovisics medical,
Boehringer-Ingelheim, Cell Care, Chengdu Kanghong Biotech,
Ciana Therap, Clearside Bio, DTx Pharma, Eloxx
Pharma, EyePoint Pharma, Gemini Therap,
Genentech, Glaukos, Graybug Vision, jCyte,
I2vision, Kala Pharma, Isarna Therap, IvericBio,
Kriya Therap, Kyowa Kirin, Linage Cell, LumiThera,
Nanoscope Therao, Novartis, Ocular Therap,
Ocugen, Oculis, Ocuphire, OcuTerra, Ocutrx
Vision, OPhthea, Optigo Bio, Oxurion, Palatin
Tech, Ray Therap, Regeneron, RetinAI, Ripple
Therap, Roche, Santen, Smilebiotek, StealthBio,
Surrozen, Thea Labs, Vanotech Corp, Verseon
Corp, VItranu, Vitro Bio, Viva Vision
Contract Research: Alcon, Allergan, Genentech, Regeneron, Novartis, Pfizer
Stock Option Holder: Allegro, DIgiSIght


The planners and managers have the following relevant financial relationships with ineligible companies:


Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Eve Wilson Nothing to disclose
Alissa Yost Nothing to disclose
Jill Adelman Nothing to disclose
Joseph Adelman Nothing to disclose
Elizabeth Tully Consulting Fee: Roche Canada, Roche Global, Alexion, Apellis

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:
For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: